Select therapeutic use:
Indications for PROSTIN E2:
For the termination of pregnancy from the 12th through the 20th gestational weeks. For the evacuation of the uterine contents in the management of missed abortion or intrauterine fetal death up to 28 weeks of gestational age. Management of nonmetastatic gestational trophoblastic disease (benign hydatidiform mole).
Insert one supp high into vagina. Remain in supine position for 10 minutes following insertion. May insert subsequent supp at 3–5 hour intervals until abortion occurs. Continuous administration for more than 2 days is not recommended.
Acute pelvic inflammatory disease. Active cardiac, pulmonary, renal or hepatic disease.
Should only be used by trained medical professional in a hospital setting. Not indicated if fetus in utero has reached the stage of viability. Not for use in cervical ripening or other indication in patients with term pregnancy. Asthma. Hypo-or hypertension. Anemia. Jaundice. Diabetes. Epilepsy. Cervicitis. Infected endocervical lesions. Acute vaginitis. Compromised (scarred) uteri. Pregnancy (Cat.C).
Concomitant other oxytocic agents: not recommended.
Vomiting, transient pyrexia (see literature re: PGEs induced pyrexia vs. endometritis pyrexia), diarrhea, nausea, headache, chills, transient decrease in BP; MI in patients with history of cardiovascular disease.